(Q33347128)

26 July 2017

title

A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer (English)

1 reference

adaptive radiation therapy

26 July 2017

main subject

0 references

1 reference

1 reference

Daniel J Sargent

5

0 references

Henry C Pitot

3

object named as

Henry C Pitot

1 reference

26 July 2017

James A Martenson

1

1 reference

26 July 2017

Antonio P G Vigliotti

2

1 reference

26 July 2017

Louis H Geeraerts

4

1 reference

26 July 2017

Michael G Haddock

6

1 reference

26 July 2017

Chirantan Ghosh

7

1 reference

26 July 2017

Michael D Keppen

8

1 reference

26 July 2017

Tom R Fitch

9

1 reference

26 July 2017

Richard M Goldberg

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

International Journal of Radiation Oncology Biology Physics

26 July 2017

published in

1 reference

26 July 2017

volume

55

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

1305-1310

1 reference

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine)

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2904399-7

7 January 2021

10.1016/S0360-3016(02)04399-7

Identifiers

DOI

1 reference

26 July 2017

1 reference